Communiqués Cessatech A/S

Actions

CESSA

DK0061411964

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 15/07/2026			Varia. 5j.	Varia. 1 janv.
17,75 ^DKK	-1,11%		-5,08%	+11,22%

12/06	Cessatech collabore avec le Rigshospitalet pour le développement du CT004	FW
12/06	Cessatech A/S et le Rigshospitalet de Copenhague s'associent pour développer une formulation intraveineuse de mélatonine (CT004) contre le délire post-anesthésique chez l'enfant	CI

Communiqués

12/06	Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children	AQ
28/05	First Quarter Report Q1-2026	AQ
30/03	Minutes from the Annual General Meeting in Cessatech A/S	AQ
13/03	Cessatech convenes its Annual General Meeting	AQ
27/02	Cessatech A/S Announces Financial Results for the Full Year 2025	AQ
02/02	Welcome to the first quarter of 2026	AQ
13/11	Cessatech: Third Quarter Report Q3-2025	PU
13/11	Third Quarter Report Q3-2025	AQ
31/10/25	Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children	PU
31/10/25	CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children	AQ
21/08/25	Cessatech: Second Quarter Report Q2-2025	PU
21/08/25	Second Quarter Report Q2-2025	AQ
14/08/25	Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children	PU
14/08/25	The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children	AQ
27/06/25	Cessatech: Cessatech Q&A – June company presentation	PU
27/06/25	Cessatech Q&A - June company presentation	AQ
19/06/25	Cessatech: Cessatech strengthens Executive Management with the promotion of Martin Juhl	PU
19/06/25	Cessatech strengthens Executive Management with the promotion of Martin Juhl	AQ
11/06/25	Cessatech: Cessatech announce completion of the directed issue of shares	PU
11/06/25	Cessatech announce completion of the directed issue of shares	AQ
28/05/25	Cessatech: Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch	PU
28/05/25	Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch	AQ
28/05/25	Cessatech: Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch	PU
28/05/25	Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch	AQ
28/05/25	Cessatech: Cessatech announces positive top-line results from its final CT001 Study 0202	PU